European Commission Grants Marketing Authorisation for Zebinix® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children - Seite 2

Eslicarbazepine acetate is indicated as adjunctive therapy in
adults, adolescents and children aged above 6 years, with
partial-onset seizures with or without secondary generalisation.

Eslicarbazepine acetate is currently marketed in Europe and Russia
by Bial and by Bial's licensee, Eisai Europe Limited, a European
subsidiary of Eisai Co Ltd under the trade name Zebinix® or Exalief®.
In the United States and Canada eslicarbazepine acetate (tradename
Aptiom®) is marketed by Sunovion Pharmaceuticals Inc under an
exclusive license from Bial.

About Epilepsy

Epilepsy is one of the most common neurological conditions in the
world, affecting approximately 6 million people in Europe, and an
estimated 50 million people worldwide.[10],[11] Epilepsy is a chronic
disorder of the brain that affects people of all ages, and is a
common neurological disorder in childhood, with approximately 100,000
children and adolescents diagnosed every year.[12] It is
characterised by abnormal discharges of neuronal activity which
causes seizures. Seizures can vary in severity, from brief lapses of
attention or jerking of muscles, to severe and prolonged convulsions.
Depending on the seizure type, seizures may be limited to one part of
the body, or may involve the whole body. Seizures can also vary in
frequency from less than one per year, to several per day. Epilepsy
has many possible causes but often the cause is unknown.

About Bial

Founded in 1924, Bial's mission is to discover, develop and
provide therapeutic solutions within the area of health. In recent
decades, Bial has strategically focused on quality, innovation and
internationalisation.

Being the partner of choice for many pharma companies, Bial is
strongly committed to therapeutic innovation, investing more than 20%
of its turnover in Research and Development (R&D) every year.

Bial has established an ambitious R&D programme centred in
neurosciences, cardiovascular system and allergic immunotherapy. The
company expects to continue to introduce new medicines and vaccines
to the market in the next years, strengthening its position worldwide
and accomplishing the company's purpose of "Caring for your Health."

For more information about Bial, please visit http://www.bial.com

About Eisai Co Ltd

Eisai Co Ltd. is a leading global research and development-based
pharmaceutical company headquartered in Japan. We define our
corporate mission as "giving first thought to patients and their
families and to increasing the benefits health care provides," which
we call our human health care (hhc) philosophy. With over 10,000